History of the development of arsenic derivatives in cancer therapy.
about
Nucleolin links to arsenic-induced stabilization of GADD5alpha mRNAArsenic trioxide for the treatment of acute promyelocytic leukaemiaArsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathwayA case of Bowen's disease and small-cell lung carcinoma: long-term consequences of chronic arsenic exposure in Chinese traditional medicine.Transcriptional activation of metalloid tolerance genes in Saccharomyces cerevisiae requires the AP-1-like proteins Yap1p and Yap8p.Arsenic binding to proteinsArsenic exposure and toxicology: a historical perspectiveArsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myelomaInhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancerEffect of arsenic trioxide on vascular endothelial cell proliferation and expression of vascular endothelial growth factor receptors Flt-1 and KDR in gastric cancer in nude mice.Chromated copper arsenate-treated wood: a potential source of arsenic exposure and toxicity in dermatology.Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to DarinaparsinProperties of realgar bioleaching using an extremely acidophilic bacterium and its antitumor mechanism as an anticancer agent.Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancersArsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo.Glutathione S-conjugates as prodrugs to target drug-resistant tumors.Arsenic trioxide - An old drug rediscovered.As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphomaArsenic sulfide as a potential anti‑cancer drug.The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.Arsenic trioxide: acute promyelocytic leukemia and beyond.A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview).Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.A potential synergy between incomplete arsenic methylation capacity and demographic characteristics on the risk of hypertension: findings from a cross-sectional study in an arsenic-endemic area of inner Mongolia, China.Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3)Arsenic trioxide for the treatment of myelodysplastic syndromes.Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administrationArsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation.ARS2 is a conserved eukaryotic gene essential for early mammalian development.The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometryInhibition of hepatitis C virus replication by arsenic trioxide.Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.Anticancer effect of arsenite on cell migration, cell cycle and apoptosis in human pancreatic cancer cellsMitochondrial hormesis links low-dose arsenite exposure to lifespan extension.
P2860
Q23924001-615932AE-957F-49B6-925B-C11791654976Q24239914-913166E7-5EB4-45EF-A7F0-17DDE4199430Q24623800-1546DD1B-333E-4FA8-93EC-6C65495A2FA6Q24814268-CFEEE026-2515-4279-A883-22B411BB6D50Q27931456-BFD93A0A-AA88-477A-85C0-8AC36D7826CBQ28389752-902C9406-F28E-4363-91E0-F35726C03019Q28392204-716E12A0-758B-42E7-AA19-C2F00B9C0AAAQ28481142-82FE5EA4-CB32-4ADA-A316-1E9930D71B2DQ28484542-B4098E80-C0A6-4B1D-A77B-0FDFB67D6CACQ33258696-4536A822-9632-4D46-8C4E-F2DAAE5BE1E0Q33312494-25389ED9-550B-4B9F-BDF1-7C914D930595Q33623706-C08F94FB-792B-4EDD-958C-BC28FA1BBC8DQ33628050-4C5BCD81-B244-48A6-B212-805591BF9554Q33637102-00DD12EB-D357-4C41-B2B1-ACE5D5B587AAQ33717094-E30C19C5-2EC1-4773-AE24-F35A57F57413Q33768666-1C28B758-C5CE-4756-A0B0-224E5E052480Q33960458-2B5E0E9C-3228-44DE-A41E-B477D5B886F7Q34024771-AA2483DA-A15A-4B01-8ABD-3892C1CE7BFCQ34054167-92965406-D046-44B2-97DE-06A0E5F007F7Q34411016-28AF7B34-C433-41BD-AACE-B97CEBE7F160Q34479660-F81BC829-D91F-4140-B2DE-1378AD75093CQ34673252-9E960A1E-FE1B-4C72-8902-95AAB5EB6C2DQ34802502-9407C65B-0D72-403F-BCBA-AA2E816A2C56Q34980350-013F2318-E948-49C7-9CA6-9D1E36C9FA5CQ35021208-B14A389B-CA71-4618-9B4C-712013E6D49AQ35155855-6FEC4D0A-B7E0-45A0-B47F-E4C1687F154AQ35223411-BDA02A41-40EC-4417-9BBF-766DDD4A8706Q35539697-7FF871E7-E237-427F-ADCD-267609EFAAF8Q35542110-6B319557-98EF-4DE1-92BB-CBB0766C82ECQ35688178-0B14C89F-11A9-48E6-BC14-6CCD73CCAFB0Q35830597-762CA12F-17BE-4F42-8271-6A2EA32CC97DQ35847861-9F5E2B4E-3F46-4176-828D-043CE5BB3F67Q36483498-599A0AD0-C38B-4A4D-AD8C-A6310F047162Q36523715-D83A09C8-636D-4CEA-8CD2-4A53ADF3C1C4Q36566386-85A2D2FC-9203-43B9-B64C-7B57211BC54DQ36670022-5496859C-9E54-4C5F-9CB6-BA63767CCB9CQ36753557-DF764C1C-4E22-4BBC-9686-8D91B0FB9757Q36824250-1B255B2D-6559-4E13-AE76-FC0D92CC4F91Q37002059-B6E9D73B-53D1-4164-B0E7-A4366DE1B9DCQ37005002-522DFBA7-7EA9-4A21-BB51-416043631F59
P2860
History of the development of arsenic derivatives in cancer therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
History of the development of arsenic derivatives in cancer therapy.
@ast
History of the development of arsenic derivatives in cancer therapy.
@en
History of the development of arsenic derivatives in cancer therapy.
@nl
type
label
History of the development of arsenic derivatives in cancer therapy.
@ast
History of the development of arsenic derivatives in cancer therapy.
@en
History of the development of arsenic derivatives in cancer therapy.
@nl
prefLabel
History of the development of arsenic derivatives in cancer therapy.
@ast
History of the development of arsenic derivatives in cancer therapy.
@en
History of the development of arsenic derivatives in cancer therapy.
@nl
P1433
P1476
History of the development of arsenic derivatives in cancer therapy.
@en
P2093
P356
10.1634/THEONCOLOGIST.6-SUPPL_2-3
P478
P577
2001-01-01T00:00:00Z